Key result
ARBs demonstrate antiproteinuric effects similar to ACE inhibitors but require long-term studies confirming clinical renoprotection.
Why the study?
Whether angiotensin II type 1 receptor antagonists have the same renoprotective effect as angiotensin-converting enzyme inhibitors in progressive renal diseases remains ill defined.
Do Angiotensin II type 1 receptor antagonists provide similar antiproteinuric and renoprotective effects as ACE inhibitors in progressive renal disease?
Do Angiotensin II type 1 receptor antagonists provide similar antiproteinuric and renoprotective effects as ACE inhibitors in progressive renal disease?
This review highlights that while ARBs show promising antiproteinuric effects comparable to ACE inhibitors, long-term studies are needed to confirm their renoprotective benefits in humans.
Answers are grounded in this paper and cite their sources.
May support ACEI renoprotection in proteinuric kidney disease; leaves open clinical translation from animal models.
Angiotensin II, the principal effector of the renin-angiotensin cascade, stimulates a variety of physiological responses that support blood pressure and renal function. Abnormal generation of angiotensin II also contributes to the pathogenesis of hypertension, arterial diseases, cardiac hypertrophy, heart failure and proteinuric progressive renal diseases. It is well recognized that angiotensin-converting enzyme inhibitors effectively limit the progression of diabetic and non-diabetic proteinuric renal diseases towards end-stage renal disease, a capacity not necessarily shared by other blood pressure lowering agents. Whether angiotensin II type 1 receptor antagonists have the same renoprotective effect as angiotensin-converting enzyme inhibitors in progressive renal diseases remains ill defined. Angiotensin II type 1 receptor antagonists as antiproteinuric agents have been used originally in animal models of renal disease progression. Results have shown that angiotensin II type 1 receptor blockers are as effective as angiotensin-converting enzyme inhibitors in normalizing proteinuria in models of renal disease. Studies in humans are very few, but those that have been undertaken report consistent antiproteinuric effects of angiotensin II type 1 receptor antagonists that are similar to those with angiotensin-converting enzyme inhibitors. Long-term studies, however, are required to examine whether the antiproteinuric effects of angiotensin II type 1 receptor antagonists can be translated into renoprotection.
No takes yet. Share an insight, caveat, or question.
Perico et al. (1998) conducted a review in Hypertension and progressive renal disease. Angiotensin II type 1 receptor antagonists vs. Angiotensin-converting enzyme inhibitors was evaluated on Antiproteinuric effects and renoprotection. Angiotensin II type 1 receptor antagonists demonstrate consistent antiproteinuric effects similar to ACE inhibitors, though long-term studies are needed to confirm clinical renoprotection.
Synapse has enriched 10 related papers. Consider them for comparative context: